The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.
Sitagliptin (Januvia®) has been accepted for use in combination with a sulphonylurea or sulphonylurea and metformin in patients with type 2 diabetes who fail to achieve adequate glucose control while taking maximal tolerated doses.
Duloxetine (Cymbalta®) has been rejected for use in generalised anxiety disorder in the absence of a submission from the manufacturer.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.